NASH
MCID: NNL006
MIFTS: 54

Non-Alcoholic Steatohepatitis (NASH)

Categories: Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Non-Alcoholic Steatohepatitis

MalaCards integrated aliases for Non-Alcoholic Steatohepatitis:

Name: Non-Alcoholic Steatohepatitis 12 52 15 17
Nonalcoholic Steatohepatitis 52 15
Nash 12 52
Non-Alcoholic Fatty Liver Disease 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0080547

Summaries for Non-Alcoholic Steatohepatitis

NIH Rare Diseases : 52 Nonalcoholic steatohepatitis , or NASH, is a common, often "silent" liver disease. It resembles alcoholic liver disease , but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis , in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes . Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Non-Alcoholic Steatohepatitis, also known as nonalcoholic steatohepatitis, is related to non-alcoholic fatty liver disease and fatty liver disease, nonalcoholic 1. An important gene associated with Non-Alcoholic Steatohepatitis is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Toll-like Receptor Signaling Pathway. The drugs Milk thistle and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 A nonalcoholic fatty liver disease that is characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without any fibrosis.

Related Diseases for Non-Alcoholic Steatohepatitis

Diseases related to Non-Alcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 763)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 32.9 TNF TLR4 PPARG PPARA PNPLA3 NR1H4
2 fatty liver disease, nonalcoholic 1 32.5 PPARA PNPLA3 MTTP INS GPT GGT1
3 alcohol use disorder 31.9 HFE GPT GGT1 CYP2E1 ALB
4 liver cirrhosis 31.9 MIR122 KRT18 HFE GPT GGT1 CYP2E1
5 hypercholesterolemia, familial, 1 31.8 NR1H4 INS GPT
6 leptin deficiency or dysfunction 31.8 TNF PPARG PPARA INS IL6 ADIPOQ
7 hyperinsulinism 31.7 PPARG PPARA INS ADIPOQ
8 gestational diabetes 31.6 TNF PPARG INS IL6 ALB ADIPOQ
9 hyperandrogenism 31.6 PPARG INS ADIPOQ
10 microvascular complications of diabetes 3 31.6 MIR21 INS ALB
11 autoimmune hepatitis 31.6 TNF KRT18 IL6 GPT GGT1 ALB
12 gastroesophageal reflux 31.6 TNF IL6 CCL2 ADIPOQ
13 eclampsia 31.6 TNF IL6 ALB
14 liver disease 31.5 TNF PPARA PNPLA3 NR1H4 MIR122 MAPK8
15 alcohol dependence 31.5 TNF PPARG GPT GGT1 CYP2E1
16 sleep disorder 31.4 TNF INS IL6 ADIPOQ
17 lipid metabolism disorder 31.4 PPARG PPARA NR1H4 MTTP MIR21 MIR122
18 hyperglycemia 31.4 PPARG INS IL6 ALB ADIPOQ
19 atrial fibrillation 31.4 MIR21 INS IL6 ALB
20 cholelithiasis 31.3 NR1H4 INS GPT GGT1 ALB
21 alcoholic hepatitis 31.3 TNF TLR4 PNPLA3 KRT18 IL6 GPT
22 portal hypertension 31.3 TNF TLR4 PNPLA3 NR1H4 INS GPT
23 kidney disease 31.3 PPARG INS IL6 CCL2 ALB ADIPOQ
24 diarrhea 31.3 TNF TLR4 IL6 GPT ALB
25 cholestasis 31.3 TNF NR1H4 IL6 GPT GGT1 ALB
26 fatty liver disease 31.3 TNF TLR4 PPARG PPARA PNPLA3 NR1H4
27 hyperuricemia 31.3 PPARG INS GPT GGT1 ALB
28 glucose intolerance 31.3 TNF PPARG INS IL6 GPT CCL2
29 chronic kidney disease 31.3 TNF TLR4 INS IL6 CCL2 ALB
30 choline deficiency disease 31.3 PPARA NR1H4 INS GPT
31 esophageal varix 31.3 GPT GGT1 ALB
32 hypothyroidism 31.3 TNF INS GPT ALB ADIPOQ
33 exanthem 31.2 TNF IL6 GPT ALB
34 gout 31.2 TNF TLR4 INS IL6 CCL2 ALB
35 peptic ulcer disease 31.2 TNF PPARG INS ALB
36 varicose veins 31.2 TNF IL6 HFE CCL2
37 hepatic encephalopathy 31.2 TNF IL6 GPT ALB
38 alpha-1-antitrypsin deficiency 31.2 TNF HFE GPT ALB
39 crohn's disease 31.2 TNF TLR4 IL6 CCL2 ALB
40 abdominal obesity-metabolic syndrome 1 31.2 PPARG PPARA NR1H4 MTTP MIR122 INS
41 end stage renal disease 31.2 TNF INS IL6 HFE ALB ADIPOQ
42 hyperthyroidism 31.2 TNF INS IL6 GPT ALB
43 peripheral vascular disease 31.2 INS IL6 CCL2 ALB
44 placenta disease 31.2 TNF TLR4 INS IL6 ADIPOQ
45 nasopharyngitis 31.1 TNF INS GPT
46 viral hepatitis 31.1 TNF TLR4 PNPLA3 MIR122 KRT18 INS
47 congestive heart failure 31.1 TNF INS IL6 ALB
48 pre-eclampsia 31.1 TNF TLR4 INS IL6 GPT ALB
49 bilirubin metabolic disorder 31.1 GPT GGT1 ALB
50 hepatitis 31.1 TNF MAPK8 KRT18 GPT GGT1

Graphical network of the top 20 diseases related to Non-Alcoholic Steatohepatitis:



Diseases related to Non-Alcoholic Steatohepatitis

Symptoms & Phenotypes for Non-Alcoholic Steatohepatitis

GenomeRNAi Phenotypes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 ALB CCL2 GGT1 HFE KRT18 MAPK8

MGI Mouse Phenotypes related to Non-Alcoholic Steatohepatitis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 ADIPOQ CYP2E1 GGT1 HFE IL6 INS
2 homeostasis/metabolism MP:0005376 10.33 ADIPOQ ALB CYP2E1 GGT1 HFE IL6
3 cardiovascular system MP:0005385 10.31 ADIPOQ ALB CYP2E1 IL6 INS MAPK8
4 cellular MP:0005384 10.3 ADIPOQ ALB GGT1 HFE IL6 INS
5 adipose tissue MP:0005375 10.25 ADIPOQ IL6 INS MAPK8 NR1H4 PNPLA3
6 immune system MP:0005387 10.25 ADIPOQ ALB CCL2 GGT1 HFE IL6
7 liver/biliary system MP:0005370 10.24 ADIPOQ ALB CYP2E1 HFE IL6 INS
8 hematopoietic system MP:0005397 10.22 ADIPOQ GGT1 HFE IL6 INS MAPK8
9 mortality/aging MP:0010768 10.2 ADIPOQ ALB CYP2E1 GGT1 HFE IL6
10 digestive/alimentary MP:0005381 10.11 ALB HFE IL6 INS MAPK8 NR1H4
11 integument MP:0010771 10.1 ADIPOQ GGT1 IL6 INS MAPK8 NR1H4
12 muscle MP:0005369 9.91 ADIPOQ ALB IL6 INS MAPK8 PPARA
13 neoplasm MP:0002006 9.81 ADIPOQ ALB CYP2E1 IL6 MAPK8 NR1H4
14 renal/urinary system MP:0005367 9.61 ADIPOQ ALB GGT1 IL6 INS MAPK8
15 skeleton MP:0005390 9.36 ADIPOQ CYP2E1 GGT1 GPT HFE IL6

Drugs & Therapeutics for Non-Alcoholic Steatohepatitis

Drugs for Non-Alcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
5
Liraglutide Approved Phase 4 204656-20-2 44147092
6
Glucagon Approved Phase 4 16941-32-5
7
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
8
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
11
Insulin aspart Approved Phase 4 116094-23-6 16132418
12
Insulin detemir Approved Phase 4 169148-63-4 5311023
13
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
14
Ribavirin Approved Phase 4 36791-04-5 37542
15
Gliclazide Approved Phase 4 21187-98-4 3475
16
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
17
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
20
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
21
Glimepiride Approved Phase 4 93479-97-1 3476
22
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
23
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
24
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
25
Lenvatinib Approved, Investigational Phase 4 417716-92-8
26
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
27
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
28
Methyltestosterone Approved Phase 4 58-18-4 6010
29
Testosterone enanthate Approved Phase 4 315-37-7 9416
30
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
31
Alogliptin Approved Phase 4 850649-61-5 11450633
32
Dulaglutide Approved, Investigational Phase 4 923950-08-7
33
Empagliflozin Approved Phase 4 864070-44-0
34
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
35
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
36
Metformin Approved Phase 4 657-24-9 14219 4091
37
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
38
Zinc Approved, Investigational Phase 4 7440-66-6 32051
39
Insulin glargine Approved Phase 4 160337-95-1
40
Saxagliptin Approved Phase 4 361442-04-8 11243969
41
Choline Approved, Nutraceutical Phase 4 62-49-7 305
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
45
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
46
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
47
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
49 Tocotrienol Investigational Phase 4 6829-55-6
50 Ipragliflozin Investigational Phase 4 761423-87-4

Interventional clinical trials:

(show top 50) (show all 1033)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
6 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
7 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
8 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
11 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
14 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
15 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
17 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
18 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
19 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
20 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
21 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
22 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
23 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
24 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
25 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
26 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
27 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
28 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
29 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
30 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
31 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
32 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
33 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
34 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
35 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
36 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
37 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
38 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
39 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
40 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
41 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
42 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
43 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
44 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
45 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
46 Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants Completed NCT04237246 Phase 4 Tacrolimus
47 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
48 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
49 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
50 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine

Search NIH Clinical Center for Non-Alcoholic Steatohepatitis

Genetic Tests for Non-Alcoholic Steatohepatitis

Anatomical Context for Non-Alcoholic Steatohepatitis

MalaCards organs/tissues related to Non-Alcoholic Steatohepatitis:

40
Liver, Testes, Kidney, Endothelial, Heart, Ovary, T Cells

Publications for Non-Alcoholic Steatohepatitis

Articles related to Non-Alcoholic Steatohepatitis:

(show top 50) (show all 8620)
# Title Authors PMID Year
1
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
2
Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. 61
32325178 2020
3
Long-term bisphenol S exposure aggravates non-alcoholic fatty liver by regulating lipid metabolism and inducing endoplasmic reticulum stress response with activation of unfolded protein response in male zebrafish. 61
32283406 2020
4
Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis. 61
32434697 2020
5
Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. 61
32145387 2020
6
Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. 61
32438122 2020
7
CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease. 61
32417373 2020
8
Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity. 61
32124215 2020
9
Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy. 61
32329579 2020
10
Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. 61
32301252 2020
11
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. 61
32329946 2020
12
Omega-3 derivatives, specialized pro-resolving mediators: Promising therapeutic tools for the treatment of pain in chronic liver disease. 61
32450460 2020
13
Involvement of activation of PLIN5-Sirt1 axis in protective effect of glycycoumarin on hepatic lipotoxicity. 61
32448510 2020
14
Are Noninvasive Methods Comparable to Liver Biopsy in Postoperative Patients After Roux-en-Y Gastric Bypass? 61
32124221 2020
15
Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. 61
31688307 2020
16
Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside. 61
32247663 2020
17
Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. 61
32268264 2020
18
Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. 61
32376267 2020
19
Pyrvinium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/β-catenin signaling crosstalk. 61
32240652 2020
20
Short-term high-fat diet intake leads to exacerbation of concanavalin A-induced liver injury through the induction of procoagulation state. 61
32083190 2020
21
Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease. 61
32228319 2020
22
Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. 61
32475638 2020
23
Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. 61
32343209 2020
24
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. 61
32147362 2020
25
The αC helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases. 61
32220799 2020
26
Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. 61
32281248 2020
27
Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis. 61
32562600 2020
28
Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio. 61
32524150 2020
29
Combined alcoholic and non-alcoholic steatohepatitis. 61
32514497 2020
30
Current and new pharmacotherapy options for non-alcoholic steatohepatitis. 61
32237916 2020
31
Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis. 61
32506513 2020
32
Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. 61
32243868 2020
33
Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. 61
32512072 2020
34
Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective? 61
32490551 2020
35
Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. 61
32455155 2020
36
Aberrant glycosaminoglycan biosynthesis by tumor suppressor EXTL2 deficiency promotes liver inflammation and tumorigenesis through Toll-like 4 receptor signaling. 61
32347583 2020
37
Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. 61
32362324 2020
38
Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. 61
32547703 2020
39
Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. 61
32530998 2020
40
Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice. 61
32200254 2020
41
Abdominal pain: Initial clinical manifestation of nonalcoholic steatohepatitis. 61
32507398 2020
42
The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. 61
32526788 2020
43
Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record. 61
32535780 2020
44
Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. 61
32246926 2020
45
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. 61
32492395 2020
46
Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. 61
32360132 2020
47
Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. 61
32150036 2020
48
S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation. 61
32556446 2020
49
6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis. 61
32392051 2020
50
Gegen Qinlian Decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways. 61
32169759 2020

Variations for Non-Alcoholic Steatohepatitis

Expression for Non-Alcoholic Steatohepatitis

Search GEO for disease gene expression data for Non-Alcoholic Steatohepatitis.

Pathways for Non-Alcoholic Steatohepatitis

Pathways related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 TNF PPARG PPARA MAPK8 INS IL6
2
Show member pathways
13.01 TNF TLR4 PPARA MAPK8 IL6 CCL2
3
Show member pathways
12.76 TNF TLR4 MAPK8 IL6 CCL2
4
Show member pathways
12.28 TNF MAPK8 IL6 CCL2
5 12.25 TNF TLR4 MAPK8 IL6
6 12.21 TNF TLR4 MAPK8 IL6
7 12.17 TNF TLR4 MAPK8 IL6
8 12.11 TNF TLR4 MAPK8 IL6 CCL2
9
Show member pathways
12.07 TNF INS IL6 GGT1 CCL2 ALB
10 11.96 TNF TLR4 IL6 CCL2
12 11.92 TNF MAPK8 IL6 CCL2
13 11.88 TNF TLR4 MAPK8 IL6 CCL2
14 11.85 TNF MAPK8 IL6 CCL2
15
Show member pathways
11.82 TNF MAPK8 INS ADIPOQ
16
Show member pathways
11.81 TNF PPARA MAPK8 INS IL6
17 11.8 PPARG INS IL6 ADIPOQ
18 11.78 TNF TLR4 IL6 CCL2
19 11.71 PPARG PPARA ADIPOQ
20 11.68 TNF TLR4 MAPK8 IL6
21 11.62 TNF PPARA MAPK8 ADIPOQ
22 11.61 TNF IL6 CCL2
23 11.55 TNF TLR4 IL6
24 11.53 MAPK8 INS IL6
25 11.49 TNF MAPK8 IL6
26 11.46 TNF IL6 CCL2
27 11.45 TNF TLR4 CCL2
28 11.43 TNF TLR4 IL6 CCL2
29 11.3 TNF TLR4 IL6
30 11.29 TNF PPARG PPARA PNPLA3 INS IL6
31 11.17 PPARG PPARA NR1H4 CYP2E1
32 10.7 TNF PPARG MAPK8 IL6 ADIPOQ

GO Terms for Non-Alcoholic Steatohepatitis

Cellular components related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNF MIR21 MIR122 INS IL6 HFE
2 RNA polymerase II transcription factor complex GO:0090575 9.13 PPARG PPARA NR1H4

Biological processes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.06 PPARG PPARA PNPLA3 NR1H4 MTTP CYP2E1
2 inflammatory response GO:0006954 10.04 TNF TLR4 NR1H4 IL6 CCL2
3 positive regulation of apoptotic process GO:0043065 10.02 TNF PPARG MIR21 MAPK8 IL6
4 negative regulation of apoptotic process GO:0043066 9.99 NR1H4 MIR21 MAPK8 KRT18 IL6 ALB
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 TNF TLR4 MIR21 CCL2
6 fatty acid metabolic process GO:0006631 9.94 PPARG PPARA GGT1 CYP2E1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.9 TNF TLR4 INS IL6
8 negative regulation of inflammatory response GO:0050728 9.88 PPARG PPARA NR1H4 ADIPOQ
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.87 TLR4 MIR21 ADIPOQ
10 response to bacterium GO:0009617 9.86 TLR4 CYP2E1 CCL2 ADIPOQ
11 response to nutrient levels GO:0031667 9.85 PPARG PPARA ADIPOQ
12 response to glucocorticoid GO:0051384 9.85 TNF IL6 ADIPOQ
13 regulation of circadian rhythm GO:0042752 9.84 PPARG PPARA MAPK8
14 glucose metabolic process GO:0006006 9.84 TNF INS ADIPOQ
15 humoral immune response GO:0006959 9.83 TNF IL6 CCL2
16 negative regulation of tumor necrosis factor production GO:0032720 9.83 TLR4 NR1H4 ADIPOQ
17 steroid hormone mediated signaling pathway GO:0043401 9.81 PPARG PPARA NR1H4
18 positive regulation of interleukin-6 production GO:0032755 9.81 TNF TLR4 IL6
19 glucose homeostasis GO:0042593 9.8 PPARG NR1H4 INS ADIPOQ
20 positive regulation of gene expression GO:0010628 9.8 TNF TLR4 MIR21 MAPK8 INS IL6
21 negative regulation of fat cell differentiation GO:0045599 9.79 TNF IL6 ADIPOQ
22 lipid homeostasis GO:0055088 9.77 PPARG PNPLA3 NR1H4
23 intracellular receptor signaling pathway GO:0030522 9.74 PPARG PPARA NR1H4
24 acute-phase response GO:0006953 9.72 INS IL6 HFE
25 negative regulation of interleukin-6 production GO:0032715 9.71 TNF TLR4 NR1H4
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.7 TNF TLR4 CCL2
27 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
28 negative regulation of cholesterol storage GO:0010887 9.69 PPARG PPARA
29 negative regulation of receptor binding GO:1900121 9.69 HFE ADIPOQ
30 positive regulation of peptide hormone secretion GO:0090277 9.68 INS HFE
31 cellular response to lipid GO:0071396 9.67 PPARG PPARA
32 negative regulation of acute inflammatory response GO:0002674 9.67 PPARG INS
33 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.66 MIR21 IL6
34 response to lipid GO:0033993 9.65 PPARG PPARA NR1H4
35 positive regulation of fatty acid oxidation GO:0046321 9.63 PPARG PPARA
36 positive regulation of cytokine secretion GO:0050715 9.63 TNF MIR21 INS
37 negative regulation of receptor biosynthetic process GO:0010871 9.62 PPARG PPARA
38 negative regulation of sequestering of triglyceride GO:0010891 9.61 PPARG PPARA
39 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR4 ADIPOQ
40 positive regulation of chemokine production GO:0032722 9.58 TNF TLR4 IL6
41 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.54 TNF MIR21 IL6
42 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.5 PPARG PPARA ADIPOQ
43 positive regulation of fatty acid metabolic process GO:0045923 9.33 PPARG PPARA ADIPOQ
44 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 TNF TLR4 MIR21 IL6
45 cellular response to lipopolysaccharide GO:0071222 9.17 TNF TLR4 NR1H4 MIR21 MAPK8 IL6

Molecular functions related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.71 TNF IL6 CCL2 ADIPOQ
2 drug binding GO:0008144 9.54 PPARG PPARA ALB
3 nuclear receptor transcription coactivator activity GO:0030374 9.5 PPARG PPARA NR1H4
4 steroid hormone receptor activity GO:0003707 9.43 PPARG PPARA NR1H4
5 nuclear receptor activity GO:0004879 9.33 PPARG PPARA NR1H4
6 fatty acid binding GO:0005504 9.13 PPARG PPARA ALB
7 transcription factor activity, direct ligand regulated sequence-specific DNA binding GO:0098531 8.8 PPARG PPARA NR1H4

Sources for Non-Alcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....